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Abstract 
The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. 
However, fewer than 5% of allergy patients receive immunotherapy because of its long duration 
and risk of allergic side effects. We aimed at enhancing s.c. immunotherapy by direct 
administration of allergen into s.c. lymph nodes. The objective was to evaluate safety and 
efficacy compared with conventional s.c. immunotherapy. In a monocentric open-label trial, 165 
patients with grass pollen-induced rhinoconjunctivitis were randomized to receive either 54 s.c. 
injections with pollen extract over 3 years [cumulative allergen dose 4,031,540 standardized 
quality units (SQ-U)] or 3 intralymphatic injections over 2 months (cumulative allergen dose 
3,000 SQ-U). Patients were evaluated after 4 months, 1 year, and 3 years by nasal provocation, 
skin prick testing, IgE measurements, and symptom scores. Three low-dose intralymphatic 
allergen administrations increased tolerance to nasal provocation with pollen already within 4 
months (P < 0.001). Tolerance was long lasting and equivalent to that achievable after standard 
s.c. immunotherapy (P = 0.291 after 3 years). Intralymphatic immunotherapy ameliorated hay 
fever symptoms (P < 0.001), reduced skin prick test reactivity (P < 0.001), decreased specific 
serum IgE (P < 0.001), caused fewer adverse events than s.c. immunotherapy (P = 0.001), 
enhanced compliance (P < 0.001), and was less painful than venous puncture (P = 0.018). In 
conclusion, intralymphatic allergen administration enhanced safety and efficacy of 
immunotherapy and reduced treatment time from 3 years to 8 weeks.  
IgE-mediated allergies, such as allergic rhinoconjunctivitis and asthma, have become highly 
prevalent, affecting up to 35% of the population in westernized countries (1). Allergen-specific 
immunotherapy, usually the s.c. administration of an allergen extract, is an effective treatment 
for allergic rhinitis, conjunctivitis, and allergy to insect venoms (2–4), conferring long-term 
benefit (5). Subcutaneous immunotherapy also interrupts progression of allergic sensitization 
from single to multiple allergens (6) and from rhinitis to asthma (7).  
Despite these benefits over symptomatic treatment, only a few allergy patients choose 
immunotherapy (8), mainly because it involves 30–70 doctor visits over 3–5 years. Such 
immunotherapy also has a risk of allergic side effects, including anaphylaxis (9), requiring 
supervision by emergency-trained personnel (2).  
We have previously shown in mice that direct intralymphatic injection, compared with s.c. or 
intramuscular injection, enhances the efficiency of class I-binding peptide vaccines (10), naked 
DNA vaccines (11), protein allergens (in preparation), and adjuvants (12). Moreover, the 
feasibility of intralymphatic vaccination has been demonstrated in clinical studies (13, 14), but 
no clinical study has compared these 2 administration routes.  
Our hypothesis was that immunotherapy is improved by direct administration of allergen into a 
lymph node, and the objectives were to evaluate the clinical feasibility and safety of allergen 
administration directly into lymph nodes, as well as to compare its efficacy with conventional 
immunotherapy. Patients with hay fever to grass pollen were injected 3 times directly into 
inguinal lymph nodes, whereas the control group was treated with conventional immunotherapy 
during 3 years (Fig. 1).  
 
 
Fig. 1.  
Trial design. Patients treated by s.c. immunotherapy received a cumulative allergen dose of 
4,031,540 SQ-U in 54 injections over 3 years. Patients treated by intralymphatic immunotherapy 
received a cumulative dose of 3,000 SQ-U within 8 weeks. All patients were evaluated at 
baseline and after 4 months, 1 year, and 3 years.  
Results 
A total of 183 patients with hay fever due to grass pollen allergy were recruited June to August 
2001.* Eighteen patients did not fulfill inclusion criteria (Fig. 2). Expecting a higher dropout rate 
in the s.c. arm, patients were asymmetrically randomized s.c./intralymphatic = 3:2. Hence, 66 
patients were randomized to the intralymphatic group, and 58 started the treatment in January 
2002. A total of 99 patients were randomized to the conventional s.c. immunotherapy group, and 
54 started the treatment. In the intralymphatic group, 19 patients were lost to follow-up, and 1 
patient withdrew consent. In the s.c. group, 17 patients were lost to follow-up, 4 patients 
withdrew consent, and 1 patient became pregnant.  
 
Fig. 2.  
Flow of patients. A total of 183 patients suffering from hay fever during the summer months 
May to July were assessed for eligibility. Eighteen did not meet inclusion criteria. A total of 165 
patients with allergy to grass pollen were randomized 3:2 into s.c. and intralymphatic 
immunotherapies, respectively. Of the 99 patients randomized into the s.c. arm, 54 showed up 
for the first injection at the baseline visit. Of the 66 patients assigned to the intralymphatic arm, 
58 showed up for the first injection at the baseline visit.  
 
Baseline characteristics of the 2 groups were similar with regard to age, sex, body mass, and 
nasal sensitivity to grass pollen (Table 1). Although more patients with asthma had been 
randomized into the intralymphatic arm, nasal sensitivity to pollen was balanced, as evidenced 
by nasal provocation testing (P = 0.373) and total subjective symptom score (P = 0.124). All 
cases of seasonal asthma were mild, requiring only occasional therapy. A total of 19 of the 58 
intralymphatically treated patients showed additional springtime hay fever with sensitization to 
trees, as well as 19 of the 54 s.c.-treated patients.  
Table 1.  
Baseline characteristics by treatment group 
 
 
Intralymphatic Administration Was Practically Painless. 
Patients receiving intralymphatic injections were asked to compare the pain of an injection into a 
lymph node to the venous puncture during the same visit (Fig. 3). On visual analogue scales 
ranging from 0 to 100 mm, the pain of intralymphatic injections averaged 9.7 ± 14.4, 
significantly less (P = 0.018; paired-samples t test) than the pain of the venous puncture (16.7 ± 
21.2).  
 
Fig. 3.  
Pain of intralymphatic (IL) immunotherapy. Patients were asked to compare the pain of injection 
into a lymph node to a venous puncture during the same visit on a visual analogue scale ranging 
from 0 to 100 mm (n = 53). Box plots show mean (dotted line), median (continuous line), 25th 
and 75th percentiles (box), 5th and 95th percentiles (whiskers), and outliers. The paired-samples 
t test showed a significant difference between intralymphatic injection and venous puncture (P = 
0.018).  
 
Intralymphatic Was Safer than s.c. Immunotherapy. 
Intralymphatic allergen injections caused fewer allergic adverse events than s.c. injections (P = 
0.001, Mann–Whitney test; Table 2). During the first 4 months of treatment, 18 mild [urticaria, 
flush, and angioedema, grades 1 and 2 according to Mueller (15)], as well as 2 severe (asthma 
requiring hospitalization, grade 3; ref. 15) allergic reactions were observed in the s.c. group. In 
the latter 2 patients, uptitration had to be continued form the last tolerated dose. In contrast, only 
6 mild allergic reactions (urticaria and angioedema) were seen after intralymphatic allergen 
administration. There was no premedication with antihistamines before injections.  
Table 2.  
Safety of intralymphatic and subcutaneous immunotherapy: Patients with adverse events 
 
Intralymphatic Immunotherapy Induced Allergen Tolerance Faster Than s.c. 
Immunotherapy. 
At baseline, both groups showed similar sensitivities to grass pollen in nasal provocation testing 
(P = 0.373). After 4 months, patients in the intralymphatic group showed an approximately 10-
fold increase of the pollen concentration required to provoke nasal symptoms (P < 0.001, 
Wilcoxon signed-rank test) (Fig. 4A). In contrast, patients in the s.c. group did not show 
significant improvement at this early time point (P = 0.425) (Fig. 4 A and B). A significant 
increase in allergen tolerance was observed only 1 year after continuous therapy (P < 0.001) 
(Fig. 4B).  
 
Fig. 4.  
Efficacy of intralymphatic (IL) vs. s.c. (SC) immunotherapy. (A) Intralymphatic therapy rapidly 
induced tolerance to grass pollen: Symptom scores during nasal provocation testing with grass 
pollen extract at baseline (●) and 4 months after initiation of treatment (○). Symbols show 
median and error bars for the 25th and 75th percentiles. The threshold shift in the intralymphatic 
group was significant (P < 0.001), whereas the shift in the s.c. group was not (P = 0.425). (B) 
Intralymphatic therapy induced long-term allergen tolerance: maximal tolerated pollen 
concentrations (pollen concentrations inducing scores ≥4) were evaluated in nasal provocation 
tests with grass pollen at baseline and after 4 months, 1 year, and 3 years. Symbols show means, 
and error bars 95% C.I.. A statistically significant increase of the maximal tolerated pollen 
concentration (P < 0.001) was already observed after 4 months and was long lasting. In contrast, 
s.c. immunotherapy did not significantly increase allergen tolerance within 4 months, but 
required 1 year of treatment. After 1-year (P = 0.856) and 3-year (P = 0.291) time points there 
was no significant difference between the 2 test groups (Mann–Whitney U test). (C) Patients in 
the intralymphatic group used less rescue medication. Rescue medication during the first year: 
antihistamine tablets (medication 1; desloratidine), nasal corticosteroid sprays (medication 2; 
mometasone furoate), asthma inhaler (medication 3; budesonide with formoterol), and 
antihistamine eye drops (medication 4; emadistinum). The percentage of patients using 
antihistamine tablets was significantly lower in intralymphatic than in s.c. patients (P = 0.020, χ2 
test with continuity correction). No significant differences were seen for other medications (nasal 
sprays P = 0.416; asthma inhaler P = 0.787; and antihistamine eye drops P = 1.000). (D) 
Intralymphatic and s.c. therapies comparably ameliorated hay fever symptoms. Patients were 
asked to score the symptoms of hay fever, congested nose, itchy nose, sneezing, red eyes, itchy 
eyes, asthma, and cough, at baseline, after 1 year, and after 3 years on a visual analogue scale 
ranging from 0 to 10. Symbols show means, and error bars 95% C.I.. Both intralymphatic (●) 
and s.c. (○) therapies significantly ameliorated subjective symptoms (within-subjects effect P < 
0.001). Amelioration in both patient groups was not significantly different (hay fever P = 0.597; 
congested nose P = 0.503; itchy nose P = 0.926; sneezing P = 0.739; red eyes P = 0.328; itchy 
eyes P = 0.678; asthma P = 0.727; and coughing P = 0.485).  
 
Allergen Tolerance Induced by Intralymphatic Immunotherapy Was Long 
Lasting. 
Amelioration of allergy symptoms after 3 intralymphatic injections within 8 weeks was long 
lasting and comparable to that achieved after 3 years of conventional immunotherapy (Fig. 4B). 
After 1 year (P = 0.856, Mann–Whitney test) and 3 years (P = 0.291), the intralymphatic groups 
did not differ significantly from the subcutaneous group.  
Patients in the Intralymphatic Group Used Less Rescue Medication. 
All patients were provided with the same rescue medication in case of symptoms during the 
pollen season: antihistamine tablets (desloratidine; Aerius), nasal sprays (mometasone furoate; 
Nasonex), asthma inhalers (budesonide combined with formoterol; Symbicort), and 
antihistamine eye drops (emadistinum; Emadine). Whether patients used rescue medications was 
recorded during the first and third pollen seasons. The percentage of patients using antihistamine 
tablets was significantly lower in the intralymphatic group (23 of 54) than in the s.c. group (35 of 
53) during the first pollen season (P = 0.020; χ2 test) (Fig. 4C), which is consistent with the faster 
induction of allergen tolerance observed in the nasal provocation test. Other rescue medications 
were rarely used, and no significant differences were observed between the 2 patient groups. 
During the pollen season of the third year, no significant differences were observed between 
intralymphatic and s.c. patients (data not shown).  
Intralymphatic and s.c. Immunotherapies Induced Comparable Subjective 
Symptom Amelioration. 
Patients recorded summertime hay fever symptoms from May to July on visual analog scales at 
baseline (pollen baseline season), after 1 year (pollen season 1), and after 3 years (pollen season 
3). The grass pollen seasons in these 3 years were not significantly different (data not shown). At 
baseline, both groups recorded similar symptom severities with no significant difference (P = 
0.124). Both intralymphatic and s.c. immunotherapies significantly ameliorated subjective 
symptoms (within-subjects effect for all symptoms P < 0.001, general linear model repeated-
measures analysis; Fig. 4D), the 2 groups being not significantly different (between-subjects 
effect hay fever P = 0.597; congested nose P = 0.503; itchy nose P = 0.926; sneezing P = 0.739; 
red eyes P = 0.328; itchy eyes P = 0.678; asthma P = 0.727; and coughing P = 0.485). There was 
no recording of symptoms at the 4-month time point, as there was no pollen season between trial 
entry and this early time point.  
Intralymphatic and s.c. Immunotherapies Reduced Skin Prick Test Reactivity 
and Specific Serum IgE Comparably. 
Titrated skin prick tests were performed at baseline and after 4 months, 1 year, and 3 years (Fig. 
5A). The wheal surface analysis showed that both intralymphatic and s.c. therapies reduced 
reactivity (P < 0.001 for all allergen doses; general linear model repeated-measures analysis). 
Consistent with reduced skin prick reactivity, timothy grass-specific serum IgE decreased 
significantly in both intralymphatic and s.c. patients (within-subjects effect P < 0.001; general 
linear model repeated-measures analysis) (Fig. 5B). The decrease in serum IgE was not 
significantly different in the intralymphatic and s.c. patient groups (between-subjects effect P = 
0.204).  
 
Fig. 5.  
Skin prick test reactivity and serum IgE. (A) Reduction of reactivity to allergen in skin prick 
tests. Wheal areas in titrated skin prick tests at baseline and after 4 months, 1 year, and 3 years. 
Both the intralymphatic (●) and s.c. (○) patients showed significantly reduced reactivity (P < 
0.001 for all allergen doses; general linear model repeated-measures analysis). Symbols show 
means, and error bars show SD. (B) Decrease of allergen-specific serum IgE. Timothy grass-
specific serum IgE (kU/l) decreased significantly both in patients receiving intralymphatic (●) 
and s.c. (○) immunotherapies (within-subjects effect P < 0.001; general linear model repeated-
measures analysis). Symbols show means, and error bars show SE. The difference between 
intralymphatic and s.c. immunotherapies was not statistically significant (between-subjects effect 
P = 0.204).  
 
Discussion 
We demonstrated that intralymphatic allergen administration enhanced safety, efficacy, and 
compliance of s.c. immunotherapy and allowed reduction of the number of injections from 54 to 
3, and reduction of the cumulative allergen dose by more than 1000-fold. This is in line with our 
preclinical observations in mice (10, 16) in terms of efficacy, and also required lower vaccine 
doses. Enhanced efficacy of targeted lymph node immunization has also been found for 
immunostimulatory complexes (17), bacteriophages (18), and a recombinant simian 
immunodeficiency virus vaccine (19). The same appears to be true for the allergen extracts used 
here. Thus, intralymphatic injection appears to generally enhance the efficacy of vaccination and 
immunotherapy. The explanation is that only a small fraction of s.c.-injected biomolecules 
reaches the draining lymph nodes to stimulate the immune response, whereas direct injection into 
a lymph node delivers all of the vaccine to the lymphatic organ.  
Intralymphatic injections are technically not difficult and not painful. Subcutaneous lymph nodes 
can be found readily by ultrasound, as their paracortical area is hypoechoic compared with the 
s.c. fat. Superficial inguinal lymph nodes are ≈1.5 cm long and only a few millimeters under the 
skin surface, even in obese patients. The pain of intralymphatic injection arose solely from 
penetrating the skin, as the sensory innervation of lymph nodes is sparse (20). The pain of an 
intralymphatic injection is comparable with s.c. injections, because the same small size (28 
gauge) needles are used. Patients in the present study rated intralymphatic injection as less 
painful than venous puncture.  
The short intralymphatic treatment enhanced patient compliance. Only 32 of 54 patients finished 
the 3 years of s.c. immunotherapy (Fig. 2). As all of the 58 intralymphatic patients received the 
full treatment consisting of 3 injections, the percentage of patients finishing the treatment was 
significantly higher (Pearson χ2 test P < 0.001). Another interesting observation was that 45 of 
the 99 patients allocated to s.c. immunotherapy did not show up for the first treatment visit. Of 
these, 16 patients reported that they had participated at randomization only because they hoped 
to be allocated to the intralymphatic arm, and another 15 said that they could not possibly fit the 
54 treatment visits into their schedules. As we had randomized more patients into the s.c. arm, 
originally expecting a higher dropout rate, this did not affect our results. In contrast, only 8 of the 
66 patients allocated to intralymphatic arm did not return for the first injection. Evidently, 
intralymphatic immunotherapy is a more attractive treatment alternative.  
The 2 treatment groups showed similar baseline characteristics with regard to age, sex, and body 
mass. Although more patients with asthma had been randomized into the intralymphatic arm, 
nasal sensitivity to grass pollen was similar in the 2 treatment groups, as evidenced by nasal 
provocation testing (P = 0.373) and total subjective symptom score (P = 0.124). If anything, one 
would expect the presence of asthma to correlate with more severe allergic rhinoconjuncitivits, 
and to therefore negatively bias the outcome in the intralymphatic group.  
Intralymphatic allergen injections were well tolerated and caused fewer allergic adverse events 
than s.c. injections. As allergen immunotherapy often causes severe allergic adverse events (9, 
21), 1 hour of medical supervision is recommended after each s.c. allergen injection, and rapid 
initial uptitration regimens with insect venom or cat dander require hospitalization. The 
enhanced safety and efficacy observed with intralymphatic therapy could solve these problems 
and make immunotherapy more convenient, shorter, and less costly.  
Intralymphatic immunotherapy reduced nasal reactivity to grass pollen already after 4 months, 
and patients in the intralymphatic group used significantly less rescue medication during the first 
pollen season than the s.c. group. Despite the short treatment period, amelioration in the 
intralymphatic patients was long lasting and not significantly different from the amelioration 
achieved after 3 years of s.c. immunotherapy.  
In conclusion, intralymphatic immunotherapy allowed a marked reduction of both number and 
dose of allergen injections necessary to induce allergen tolerance, making the treatment shorter 
and safer. The practically painless procedure also enhanced patient compliance, thus making 
intralymphatic immunotherapy an interesting alternative to conventional s.c. treatment.  
Methods 
Statistical Considerations. 
Sample size calculations were based on the study objective efficacy. As patients receiving s.c. 
immunotherapy were injected with a ≈1000-fold lower cumulative allergen dose, the objective 
safety comparison was anticipated to require lower patient numbers than efficacy comparison. 
Nasal provocation testing was planned to detect significant differences (β = 20%, 2-sided α = 
0.05) if change from baseline scores differed by 0.7 or greater (variance = 0.9) across treatment 
groups. A total sample size of 165 allowed for loss to follow-up. Expecting a higher dropout rate 
during 3 years of s.c. immunotherapy, randomization of s.c. vs. intralymphatic immunotherapy 
was performed at a 3:2 proportion by having the patients draw lots (99 s.c. and 66 intralymphatic 
identical-looking folded lots were mixed together in a blinding bag). Drawing a lot and starting 
the corresponding treatment constituted admission to the trial, and intention-to-treat analysis was 
conducted on the basis of that allocation. Parametric data were evaluated using a Student t test or 
the general linear model. Independent nonparametric data were compared using the Mann–
Whitney U test or χ2 test. The Wilcoxon signed-rank test or Friedman test was applied for paired 
data.  
Eligibility. 
Study participants were recruited by newspaper ads searching for patients with seasonal 
rhinoconjunctivitis but without perennial allergies. At screening, skin prick tests with all frequent 
aeroallergens were performed. Inclusion criteria were history of allergic rhinoconjunctivitis in 
summer, age 18 to 65 years, positive skin prick test to grass pollen, and written informed 
consent. Springtime hay fever and skin prick test positivity to tree pollen (birch, hazel, and alder) 
were not exclusion criteria. Skin prick test reactivity to cat dander or house dust mite with no 
clinically significant symptoms were not exclusion criteria. Exclusion criteria were blood 
donation or surgery within the previous 30 days; use of investigational drugs within the previous 
90 days; pregnancy or nursing; mastocytosis; significant cardiovascular, hepatic, renal, 
autoimmune, hematological, or active infectious disease; and history of malignancy, 
hypertension, immunosuppressive agents, β blockers, ACE inhibitors, and tricyclic 
antidepressants. Pulmonary disease, including perennial asthma and perennial use of inhalative 
corticosteroids, was an exclusion criterion, whereas seasonal allergic asthma was not.  
Treatment and Follow-up Procedures. 
One group of patients received three 0.1-ml injections with 1,000 standardized quality units (SQ-
U) of aluminum hydroxide-adsorbed grass pollen extract at day 0 and after 4 and 8 weeks 
(Alutard SQ; ALK-Abelló). A superficial inguinal lymph node was aseptically and slowly 
injected under ultrasound guidance. Aspirations were made before the injection to avoid 
inadvertent intravascular administration.  
The other group of patients received a total of 54 s.c. injections over 3 years (cumulative dose of 
4,031,540 SQ-U). The doses of aluminum-adsorbed grass pollen extracts (Alutard SQ) were 
increased weekly for 16 weeks (Fig. 1). After the maintenance dose (100,000 SQ-U) was 
reached, injections were given monthly.  
Nasal provocation tests were performed according to standard procedures (22). After adaptation 
to room temperature for 10 min, an anterior rhinoscopy was performed to determine baseline 
values. Then, 50 μl of isotonic test solutions was administered to the middle nose conch using a 
pipette. Patients then were challenged with allergen diluent—100, 1,000, 10,000, or 100,000 SQ-
U aqueous grass pollen extract (Aquagen SQ) in 10-min intervals. A symptom score ranging 
from 0–6 points was recorded (22): nasal secretion (none = 0 points, mild = 1 point, severe = 2 
points), sneezing (0–2 times = 0 points, 3–5 times = 1 point, >5 times = 2 points), remote 
symptoms (none = 0 points, lacrimation or pruritus of the ear or palate = 1 point, conjunctivitis, 
chemosis, urticaria, coughing, or shortness of breath = 2 points).  
The pollen concentration inducing a score ≥4 was defined as the maximal tolerated pollen 
concentration. In these patients, the pollen dose was not further escalated for safety reasons, and 
patients were assumed to have the maximal score of 6 at the next higher concentration. If 
patients did not reach a score ≥4 with the highest test concentration of 100,000 SQ-U, the 
maximum tolerated dose was 1,000,000 SQ-U. Skin prick tests were performed according to the 
European Academy of Allergology and Clinical Immunology recommendations (23). A total of 
30 μl serially diluted of grass pollen allergens (Soluprick Alutard SQ; ALK-Abelló) was applied 
on the volar forearm. Tests were evaluated after 15 min. Wheals were outlined on the skin with a 
pen, blotted onto a cellophane tape, and the areas of wheals and flares were assessed by 
planimetry (24). On a 100-mm scale, patients were asked to record the severity of hay fever, 
asthma, nasal congestion, nasal itching, sneezing, red eyes, ocular itching, and dry cough. Serum 
IgE was measured by UniCAP (Amersham Pharmacia) for grass–pollen mix and timothy grass 
(g6).  
The study was performed from June 2001 to March 2005 at the University Hospital Zurich, 
Switzerland, according to International Conference on Harmonization Good Clinical Practice 
guidelines and the Declaration of Helsinki. It was approved by the local ethics committee and 
Swissmedic was notified. Written informed consent was obtained from all patients before 
enrolment.  
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